glp 1 drugs and kidney function GLP-1 agonists in the treatment of chronic disease in type 2 diabetes obesity GLP-1 and the kidney: from

Investigations persist into innovative delivery methods and formulations that may improve absorption, prolong duration of effect, or provide alternate routes of administration

Kim and Egan (2008)

It also removes supply chain complications linked to shipping injectables

Patients with type 2 diabetes and dyslipidaemia represent the most appropriate group for GLP-1 therapy when glycaemic targets are not achieved with other treatments

The chance of vision loss is very small

Change (rotate) your injection site within the area you choose with each injection to reduce your risk of getting lumps under the skin (cutaneous amyloidosis)